Indications |
Oral Hyperlipidaemias Adult: 200 mg tid, may increase dose gradually over 5-7 days. Maintenance: 200 mg bid. As modified-release preparation: 400 mg daily. Renal impairment: Contraindicated in dialysis patients.
|
||||||||
Contraindications |
Advanced liver disease, primary biliary cirrhosis; gallstones or gallbladder disorders; severe renal insufficiency, hypoalbuminaemia. Pregnancy, lactation. | ||||||||
Warnings / Precautions |
Renal impairment; children. In patients receiving cholestyramine, the 2 drugs must be separated by 2 hr. History of jaundice or hepatic disorder; renal impairment (reduce dose); hypoalbuminaemia or nephrotic syndrome. | ||||||||
Adverse Reactions |
GI upset; pruritus, urticaria, alopoecia, impotence; vertigo, fatigue; increased serum transaminases. Potentially Fatal: Leucopenia, thrombocytopenia; myotoxicity. |
||||||||
Drug Interactions |
Cholestyramine inhibits bezafibrate absorption. Potentially Fatal: Enhanced effects of oral anticoagulants. See Below for More bezafibrate Drug Interactions |
||||||||
Mechanism of Actions |
Bezafibrate causes significant reduction in plasma by reducing the conc of very low-density lipoproteins (VLDL). It also increases the activity of lipoprotein lipase and several other enzymes. Absorption: Readily absorbed from the GI tract (oral). Distribution: Protein-binding: 95%. Excretion: Urine (50% unchanged drug and metabolites); faeces (small amounts); 2 hr (elimination half-life). |
||||||||
Administration |
Should be taken with food. |
||||||||
Storage Conditions |
Oral: Store below 25°C. | ||||||||
ATC Classification |
C10AB02 - bezafibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia. | ||||||||
Storage |
Oral: Store below 25°C. | ||||||||
Available As |
|
Bezafibrate
Post Review about Bezafibrate Click here to cancel reply.
Bezafibrate Containing Brands
Bezafibrate is used in following diseases
Drug - Drug Interactions of Bezafibrate
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.